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Colorectal cancer (CRC) is the third most common malignancy in males and the second most 
common cancer worldwide. Chronic colonic inflammation is a known risk factor for CRC. 
Cocoa contains many polyphenolic compounds that have beneficial effects in humans. The 
objective of this study is to explore the antioxidant properties of cocoa in the mouse model of 
azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated cancer, 
focusing on the activation of Nrf2 signaling. Mice were treated with AOM/DSS and 
randomized to receive either a control diet or a 5 and 10% cocoa diet during the study period. 
On day 62 of the experiment, the entire colon was processed for biochemical and 
histopathological examination and further evaluations. Increased levels of malondialdehyde 
(MDA) were observed in AOM/DSS-induced mice; however, subsequent administration of 
cocoa decreased the MDA. Enzymatic and nonenzymatic antioxidants, such as superoxide 
dismutase, catalase, glutathione peroxidase and glutathione reductase, were decreased in the 
AOM/DSS mice. Cocoa treatment increases the activities/levels of enzymatic and 
nonenzymatic antioxidants. Inflammatory mediators, such as inducible nitric oxide synthase 
(iNOS) and cyclooxygenase (COX)-2, were elevated during AOM/DSS-induction, and 
treatment with 5 and 10% cocoa effectively decreases the expression of iNOS and COX-2. 
The NF-E2-related factor 2 and its downstream targets, such as NQO1 and UDP-GT, were 
increased by cocoa treatment. The results of our study suggest that cocoa may merit further 
clinical investigation as a chemopreventive agent that helps prevent CAC. 
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